Literature DB >> 24978925

De novo CD3 negative hepatosplenic T-cell lymphoma: diagnostic challenges and pitfalls.

Lucy Harn Kapur1, Yasser Khaled, Melhem Solh, David Ward, Chung-Che Chang.   

Abstract

Hepatosplenic T-cell lymphoma is a rare and aggressive peripheral T-cell malignancy that is distinctively characterized by sinusoidal infiltration of mature medium-sized T lymphocytes in the spleen and liver. The neoplastic cells are classically surface CD3(+), CD2(+), CD5(-), CD4(-), and CD8(+/-) and manifest variable expression of markers associated with natural killer (NK) cells such as CD16 and CD56. In this article, we report the first case to date of a newly diagnosed de novo surface CD3(-) hepatosplenic T-cell lymphoma with circulating blastlike neoplastic cells expressing NK-cell-associated markers. The lack of surface CD3 expression, together with the expression of NK-cell-associated markers and the leukemic presentation, leads to significant diagnostic challenges in differentiating this CD3(-) hepatosplenic T-cell lymphoma from NK-cell neoplasms, in particular aggressive NK-cell leukemia. The related literature is reviewed, and the approaches for adequate diagnosis of this novel situation are described.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24978925     DOI: 10.5858/arpa.2013-0074-CR

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  2 in total

1.  EBV-negative Aggressive NK-cell Leukemia/Lymphoma: Clinical, Pathologic, and Genetic Features.

Authors:  Alina Nicolae; Karthik A Ganapathi; Trinh Hoc-Tran Pham; Liqiang Xi; Carlos A Torres-Cabala; Nahid M Nanaji; Hongbin D Zha; Zhen Fan; Sybil Irwin; Stefania Pittaluga; Mark Raffeld; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

2.  Molecular mechanism of ovarian toxicity of Hook.F. a study based on network pharmacology and molecular docking.

Authors:  Zhiqiang Wang; Caixia Gong; Zhenbin Li
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2022-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.